Related Experiment Video
Updated: Jul 27, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
[Changes in serum lipoproteins in patients with ischemic heart disease at an early age]
Insights
Hyperlipidemia (HLP) and dyslipoproteinemia (DLP) are prevalent in ischemic heart disease (IHD) patients, characterized by altered lipoprotein profiles. These lipid abnormalities correlate with IHD progression, highlighting their clinical significance.
Area of Science:
- Cardiovascular Medicine
- Clinical Biochemistry
- Lipid Metabolism
Context:
- Chronic ischemic heart disease (IHD) affects a significant population, with lipid profiles playing a crucial role in its pathogenesis.
- Understanding lipoprotein abnormalities in IHD is essential for risk stratification and management.
Purpose:
- To investigate the prevalence and characteristics of hyperlipidemia (HLP) and dyslipoproteinemia (DLP) in patients with chronic IHD.
- To analyze the association between specific lipoprotein profiles and the severity of IHD.
Summary:
- Serum lipoprotein profiles were analyzed in 37 IHD patients and 100 healthy controls. HLP/DLP were found in 86.5% of IHD patients, with Type IV, IIB, and IIa being most common.
- Key findings include decreased HDLP-Chol and increased HDLP-Tg, leading to a reduced intralipoprotein index (1(2)).
- Lipoprotein index II (LDLP-Chol and VLDLP-Chol/HDLP-Chol) was significantly elevated in all IHD groups, including those with normolipoproteinemia (NLP).
Impact:
- The study reveals a strong correlation between specific HLP types and IHD severity, with Type IV HLP and DLP decreasing as IHD progresses, while Types IIa and IIb increase.
- Elevated lipoprotein index II serves as a significant indicator across all IHD stages, even with normal overall lipid levels.
- These findings underscore the importance of comprehensive lipoprotein profiling in managing IHD and suggest potential biomarkers for disease progression.
Abstract:
The serum lipoprotein profile was determined in 37 patients with chronic ischemic heart disease (IHD) and 100 practically healthy subjects, aged from 18 to 45. HLP was found in 59.5 per cent of the patients examined, 50 per cent in males and 100 per cent in females. Type IV has the highest incidence (54.5%), followed by type IIB(36.4%) and type IIa (9.1 per cent). In 27 per cent of the patients with no HLP determined, less significant changes in LDLP and VLDLP were found, admitted to be dyslipoproteinemia (DLP). HLP and DLP were confirmed in 86.5 per cent of the patients examined. In all patients serum concentration of HDLP-Chol was decreased (mostly in DLP and type IV HLP), whereas the level of HDLP-Tg was increased in most of the cases. As a result, the intralipoprotein index 1(2)(=HDLP-Chol/HDLP-Tg) was decreased, reaching the lowest values in IIa and type IV HLP. The only index of all studied, being changed (elevated) with a statistical significance in all groups of patients with IHD, in those with normolipoproteinemia (NLP) including, was the lipoprotein index II(=LDLP-Chol and VLDLP-Chol/HDLP-Chol). With the morbid process progressing, assessed by ECG data, the functional stage of stenocardia, the degree of the constriction and the number of the pathologically altered coronary arteries, the incidence of NLP, DLP and type IV HLP distinctly decreased, whereas IIa and IIB type HLP increased.
Related Concept Videos
Inflammation
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipids: Dietary Sources and Requirements
Cholesterol: Significance and Regulation
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management

